110.17
1.43 (1.32%)
| Penutupan Terdahulu | 108.74 |
| Buka | 108.62 |
| Jumlah Dagangan | 2,411,030 |
| Purata Dagangan (3B) | 2,549,613 |
| Modal Pasaran | 14,308,264,960 |
| Harga / Jualan (P/S) | 15.92 |
| Harga / Buku (P/B) | 55.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Feb 2026 |
| Margin Keuntungan | -53.82% |
| Margin Operasi (TTM) | -54.33% |
| EPS Cair (TTM) | -3.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.80% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | -272.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.71 M |
| Pulangan Atas Aset (ROA TTM) | -18.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -4,584.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Guardant Health, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -1.20 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.53% |
| % Dimiliki oleh Institusi | 97.57% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 155.00 (Leerink Partners, 40.69%) | Beli |
| Median | 120.00 (8.92%) | |
| Rendah | 105.00 (Evercore ISI Group, -4.69%) | Pegang |
| Purata | 124.23 (12.76%) | |
| Jumlah | 12 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 101.78 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stifel | 09 Jan 2026 | 120.00 (8.92%) | Beli | 110.17 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (-4.69%) | Pegang | 101.87 |
| 30 Oct 2025 | 90.00 (-18.31%) | Beli | 92.41 | |
| Guggenheim | 05 Jan 2026 | 115.00 (4.38%) | Beli | 101.87 |
| Canaccord Genuity | 22 Dec 2025 | 125.00 (13.46%) | Beli | 101.34 |
| 30 Oct 2025 | 100.00 (-9.23%) | Beli | 92.41 | |
| Mizuho | 17 Dec 2025 | 120.00 (8.92%) | Beli | 97.47 |
| Barclays | 15 Dec 2025 | 120.00 (8.92%) | Beli | 102.67 |
| 30 Oct 2025 | 85.00 (-22.85%) | Beli | 92.41 | |
| JP Morgan | 15 Dec 2025 | 120.00 (8.92%) | Beli | 102.67 |
| Leerink Partners | 15 Dec 2025 | 155.00 (40.69%) | Beli | 102.67 |
| Wells Fargo | 15 Dec 2025 | 120.00 (8.92%) | Beli | 102.67 |
| BTIG | 12 Dec 2025 | 140.00 (27.08%) | Beli | 102.07 |
| 30 Oct 2025 | 100.00 (-9.23%) | Beli | 92.41 | |
| Citigroup | 11 Dec 2025 | 135.00 (22.54%) | Beli | 101.38 |
| 30 Oct 2025 | 100.00 (-9.23%) | Beli | 92.41 | |
| Morgan Stanley | 02 Dec 2025 | 130.00 (18.00%) | Beli | 103.87 |
| UBS | 30 Oct 2025 | 110.00 (-0.15%) | Beli | 92.41 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | - | - | 0 | 0 |
| MONROE TERILYN J. | - | 111.98 | -8,808 | -986,320 |
| TARIQ MUSA | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,808 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -986,320 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 111.98 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | Pengarah | 17 Jan 2026 | Pelaksanaan pilihan | 232 | - | - |
| MONROE TERILYN J. | Pegawai | 15 Jan 2026 | Dibuang (-) | 8,808 | 111.98 | 986,320 |
| MONROE TERILYN J. | Pegawai | 15 Jan 2026 | Pelaksanaan pilihan | 17,379 | - | - |
| TARIQ MUSA | Pengarah | 15 Jan 2026 | Pelaksanaan pilihan | 250 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |